Dignify Therapeutics Overview
- Year Founded
-
2013
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$800K
- Investors
-
10
Dignify Therapeutics General Information
Description
Developer of novel drug therapies designed to restore voluntary control of excretory function to neurologically impaired people. The company offers effective and convenient pharmaceutical agents that trigger the voiding of bladder and bowel contents when the person wishes, enabling patients with spinal cord injury, spina bifida, and other neurological conditions to regain autonomy over essential bodily functions.
Contact Information
Website
www.dignifytherapeutics.comCorporate Office
- 2 Davis Drive, Research Triangle Park
- PO Box 13169
- Durham, NC 27709
- United States
Corporate Office
- 2 Davis Drive, Research Triangle Park
- PO Box 13169
- Durham, NC 27709
- United States
Dignify Therapeutics Timeline
Dignify Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Later Stage VC | 23-Sep-2026 | $800K | Completed | Pre-Clinical Trials | ||
| 15. Accelerator/Incubator | 22-Oct-2024 | Completed | Pre-Clinical Trials | |||
| 14. Later Stage VC | 03-Jan-2024 | Completed | Pre-Clinical Trials | |||
| 13. Grant | 01-Jan-2023 | Completed | Pre-Clinical Trials | |||
| 12. Debt - PPP | 28-Apr-2020 | Completed | Pre-Clinical Trials | |||
| 11. Grant | 01-Jan-2020 | Completed | Pre-Clinical Trials | |||
| 10. Grant | 30-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 9. Grant | 01-Jan-2019 | Completed | Pre-Clinical Trials | |||
| 8. Grant | 07-Aug-2017 | $3.47M | $5.25M | Completed | Pre-Clinical Trials | |
| 7. Early Stage VC | 25-Feb-2015 | $3.45M | $5.25M | Completed | Pre-Clinical Trials |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Dignify Therapeutics Comparisons
Industry
Financing
Details
Dignify Therapeutics Competitors (16)
One of Dignify Therapeutics’s 16 competitors is Neurona Therapeutics, a Formerly VC-backed company based in South San Francisco, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Neurona Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Cytokinetics | Formerly VC-backed | South San Francisco, CA | ||||
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| TauRx Pharmaceuticals | Private Equity-Backed | Aberdeen, United Kingdom | ||||
| Curemark | Venture Capital-Backed | New York, NY |
Dignify Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Dignify Therapeutics Patents
Dignify Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2022207425-A1 | Compositions and methods for inducing defecation | Pending | 15-Jan-2021 | ||
| AU-2022207425-A9 | Compositions and methods for inducing defecation | Pending | 15-Jan-2021 | ||
| CA-3202947-A1 | Compositions and methods for inducing defecation | Pending | 15-Jan-2021 | ||
| EP-4277614-A1 | Compositions and methods for inducing defecation | Pending | 15-Jan-2021 | ||
| EP-4277614-A4 | Compositions and methods for inducing defecation | Pending | 15-Jan-2021 | A61K31/165 |
Dignify Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Dignify Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Praxis Spinal Cord Institute | Accelerator/Incubator | |||
| National Institutes of Health | Government | |||
| National Institutes of Neurological Disorders and Stroke | Government | |||
| National Institute on Aging | Government | |||
| Eshelman Ventures | Venture Capital | Minority |
Dignify Therapeutics FAQs
-
When was Dignify Therapeutics founded?
Dignify Therapeutics was founded in 2013.
-
Where is Dignify Therapeutics headquartered?
Dignify Therapeutics is headquartered in Durham, NC.
-
What is the size of Dignify Therapeutics?
Dignify Therapeutics has 14 total employees.
-
What industry is Dignify Therapeutics in?
Dignify Therapeutics’s primary industry is Drug Discovery.
-
Is Dignify Therapeutics a private or public company?
Dignify Therapeutics is a Private company.
-
What is Dignify Therapeutics’s current revenue?
The current revenue for Dignify Therapeutics is .
-
How much funding has Dignify Therapeutics raised over time?
Dignify Therapeutics has raised $9M.
-
Who are Dignify Therapeutics’s investors?
Praxis Spinal Cord Institute, National Institutes of Health, National Institutes of Neurological Disorders and Stroke, National Institute on Aging, and Eshelman Ventures are 5 of 10 investors who have invested in Dignify Therapeutics.
-
Who are Dignify Therapeutics’s competitors?
Neurona Therapeutics, Cytokinetics, NeuroNascent, TauRx Pharmaceuticals, and Curemark are some of the 16 competitors of Dignify Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
